美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Novelion Therapeutics Inc

0.6800

0.0000

成交量：- -

成交额：- -

市值：1,334.09万

市盈率：-0.12

高：0.6800

开：0.6800

低：0.6800

收：0.6800

52周最高：2.35

52周最低：0.5400

股本：1,961.89万

流通股本：1,244.84万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-5.6822

每股收益(LYR):-5.7584

净资产收益率：162.64%

总资产收益率：-5.36%

市净率：-0.15

市盈率(LYR):-0.12

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Novelion Therapeutics Inc

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.novelion.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Novelion Therapeutics Inc.是一家专注于创新性眼科疾病类产品的研发和商业化的企业，该产品能够解决世界范围内患者和临床医师未遇到的医学血药。公司专注于合成类维生素A项目的研发、具有知识产权的定时药物输送系统的研发以及商业药物维替泊芬（Visudyne）在美国的市场营销，该药可用于治疗湿性年龄相关性黄斑变性。公司具有一个商业药物，即维替泊芬（Visudyne）。该药物采用光激发的光力学疗法治疗被称为湿性年龄相关性黄斑变性（AMD）的眼科疾病，这也是在北美和欧洲50岁以上人群失明的主要原因。维替泊芬还可用于治疗合并病理性近视（高度近视）（pathologic myopia）中的脉络膜新生血管（CNV）以及假性眼睛组织胞浆菌病。维替泊芬由Novelion Therapeutics公司和诺华制药股份公司（Novartis Pharma AG）共同研制，并在全球超过80个国家进行营销和销售。Novelion Therapeutics公司于1981年依照不列颠哥伦比亚省相关法律条文注册成立。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NVLN/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLN\",,,,,undefined,":{"symbol":"NVLN","market":"US","secType":"STK","nameCN":"Novelion Therapeutics Inc","latestPrice":0.68,"timestamp":1570564800000,"preClose":0.68,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":12448376,"shares":19618946,"eps":-5.682162,"marketStatus":"退市","change":0,"latestTime":"05-18 07:54:57 EDT","open":0.68,"high":0.68,"low":0.68,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.682162,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.68,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLN\",,,,,undefined,":{"symbol":"NVLN","floatShares":12448376,"roa":"-5.36%","roe":"162.64%","lyrEps":-5.758398,"shares":19618946,"dividePrice":0,"high":0.68,"amplitude":0,"preClose":0.68,"low":0.68,"week52Low":0.54,"pbRate":"-0.15","week52High":2.35,"institutionHeld":0.3679,"latestPrice":0.68,"eps":-5.682162,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.682162,"open":0.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-03-14","symbol":"NVLN","fiscalQuarterEnding":"2018/12","expectedEps":-0.9,"name":null,"time":"","type":"earning","dateTimestamp":1552536000000,"reportTimeType":"","actualEps":-1.03},{"market":"US","date":"2018-11-09","symbol":"NVLN","fiscalQuarterEnding":"2018/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1541739600000,"reportTimeType":"","actualEps":-1.32},{"market":"US","date":"2018-08-07","symbol":"NVLN","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533614400000,"reportTimeType":"","actualEps":-0.64},{"market":"US","date":"2018-05-10","symbol":"NVLN","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"","actualEps":-1.76},{"market":"US","date":"2018-03-15","symbol":"NVLN","fiscalQuarterEnding":"2017/12","expectedEps":-1.58,"name":null,"time":"","type":"earning","dateTimestamp":1521086400000,"reportTimeType":"","actualEps":-1.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVLN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.novelion.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novelion Therapeutics Inc.是一家专注于创新性眼科疾病类产品的研发和商业化的企业，该产品能够解决世界范围内患者和临床医师未遇到的医学血药。公司专注于合成类维生素A项目的研发、具有知识产权的定时药物输送系统的研发以及商业药物维替泊芬（Visudyne）在美国的市场营销，该药可用于治疗湿性年龄相关性黄斑变性。 公司具有一个商业药物，即维替泊芬（Visudyne）。该药物采用光激发的光力学疗法治疗被称为湿性年龄相关性黄斑变性（AMD）的眼科疾病，这也是在北美和欧洲50岁以上人群失明的主要原因。维替泊芬还可用于治疗合并病理性近视（高度近视）（pathologic myopia）中的脉络膜新生血管（CNV）以及假性眼睛组织胞浆菌病。维替泊芬由Novelion Therapeutics公司和诺华制药股份公司（Novartis Pharma AG）共同研制，并在全球超过80个国家进行营销和销售。Novelion Therapeutics公司于1981年依照不列颠哥伦比亚省相关法律条文注册成立。","exchange":"NASDAQ","name":"Novelion Therapeutics Inc","nameEN":"Novelion Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NVLN\",market:\"US\",,,undefined,":null}}